COVID-19 Response: Local Logistics     National Effort

Thioaptamers targeting dengue virus type-2 envelope protein domain III. [Protein Technology Core]

You are here

COVID-19 Response: Local Logistics     National Effort

TitleThioaptamers targeting dengue virus type-2 envelope protein domain III. [Protein Technology Core]
Publication TypeJournal Article
Year of Publication2014
AuthorsGandham SHari A, Volk DE, Lokesh GLR, Neerathilingam M, Gorenstein DG
JournalBiochem Biophys Res Commun
Volume453
Issue3
Pagination309-15
Date Published2014 Oct 24
ISSN1090-2104
KeywordsAntibodies, Neutralizing, Antiviral Agents, Aptamers, Nucleotide, Base Sequence, Dengue Virus, Magnetic Resonance Spectroscopy, Viral Envelope Proteins
Abstract

Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154nM.

DOI10.1016/j.bbrc.2014.09.053
Alternate JournalBiochem. Biophys. Res. Commun.
PubMed ID25261724
PubMed Central IDPMC4272640
Grant ListR01 DE024392 / DE / NIDCR NIH HHS / United States
HHSN272200800048C / AI / NIAID NIH HHS / United States
U01 AI054827 / AI / NIAID NIH HHS / United States
U54 CA151668 / CA / NCI NIH HHS / United States
RC2 GM092599 / GM / NIGMS NIH HHS / United States
R01 CA128797 / CA / NCI NIH HHS / United States
R90 DK071505 / DK / NIDDK NIH HHS / United States
HHSN268201000037C / HV / NHLBI NIH HHS / United States
T90 DK070109 / DK / NIDDK NIH HHS / United States
UL1 TR000371 / TR / NCATS NIH HHS / United States